Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash & Current Investments: 2013-2024

Historic Cash & Current Investments for Zevra Therapeutics (ZVRA) over the last 10 years, with Dec 2024 value amounting to $69.5 million.

  • Zevra Therapeutics' Cash & Current Investments rose 123.22% to $199.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.2 million, marking a year-over-year increase of 106.20%. This contributed to the annual value of $69.5 million for FY2024, which is 2.60% up from last year.
  • As of FY2024, Zevra Therapeutics' Cash & Current Investments stood at $69.5 million, which was up 2.60% from $67.7 million recorded in FY2023.
  • Zevra Therapeutics' Cash & Current Investments' 5-year high stood at $112.3 million during FY2021, with a 5-year trough of $4.2 million in FY2020.
  • For the 3-year period, Zevra Therapeutics' Cash & Current Investments averaged around $73.2 million, with its median value being $69.5 million (2024).
  • As far as peak fluctuations go, Zevra Therapeutics' Cash & Current Investments spiked by 2,566.65% in 2021, and later dropped by 26.69% in 2022.
  • Zevra Therapeutics' Cash & Current Investments (Yearly) stood at $4.2 million in 2020, then soared by 2,566.65% to $112.3 million in 2021, then decreased by 26.69% to $82.4 million in 2022, then dropped by 17.76% to $67.7 million in 2023, then rose by 2.60% to $69.5 million in 2024.